BioSpace News Archive

Pharm Country

Trevi Therapeutics to Participate in Upcoming Conferences

Trevi Therapeutics, Inc. today announced that senior management will be attending investor, business development and medical conferences in May and June.

May 9, 2024
·
3 min read
Business

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024

Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2024 operating results on Wednesday, May 15, 2024, before the open of the U.S. financial markets.

May 9, 2024
·
1 min read
Business

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune diseases, today reported financial results and business highlights for the first quarter ended March 31, 2024.

May 9, 2024
·
13 min read
Drug Development

Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea

Apnimed announced the early completion of enrollment in its LunAIRo Phase 3 study designed to examine the efficacy and safety of its lead candidate AD109 compared to placebo at six months and one year.

May 9, 2024
·
7 min read
Business

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, reported business highlights and financial results for the first quarter ending March 31, 2024.

May 9, 2024
·
19 min read
Business

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, announced its financial results for the first quarter of 2024.

May 9, 2024
·
16 min read
Business

Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics, Inc. announced financial results for the first quarter ending March 31, 2024, and provided a corporate update.

May 9, 2024
·
11 min read
Pharm Country

Optinose Announces $55 Million Registered Direct Offering

Optinose announced that it has entered into agreements for the sale of approximately $55 million of its common stock and pre-funded common stock warrants to a group of existing and new institutional investors in a registered direct offering.

May 9, 2024
·
8 min read
Business

Charles River Laboratories Announces First-Quarter 2024 Results

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.7% from $1.03 billion in the first quarter of 2023.

May 9, 2024
·
29 min read
Business

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Black Diamond Therapeutics, Inc., a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

May 9, 2024
·
8 min read